Welcome to our dedicated page for BFRA news (Ticker: BFRA), a resource for investors and traders seeking the latest updates and insights on BFRA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BFRA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BFRA's position in the market.
Biofrontera AG (NASDAQ: BFRA) reported its Q1 2020 results, showing total revenue of €6.5 million, a 5% decrease from €6.8 million in Q1 2019, significantly impacted by the COVID-19 pandemic. The company faced a 19% decline in product sales in the USA, totaling €4.2 million. Operating costs rose sharply, leading to a loss before tax of €5.5 million (up 109% year-over-year). Despite challenges, a licensing agreement with Maruho Co. Ltd. provided €6 million to support liquidity. The outlook for 2020 remains uncertain due to ongoing pandemic effects.
Biofrontera AG (NASDAQ: BFRA) commented on its litigation against DUSA Pharmaceuticals in California. The company initially sued DUSA for unfair competition, alleging excessive product sampling and inflated pricing. Biofrontera's litigation strategy has been reevaluated due to COVID-19, leading to resource cessation on this lawsuit after successfully stopping DUSA's distribution method. However, the ongoing litigation brought by DUSA in Massachusetts remains unaffected. The company emphasizes its commitment to ensuring competitive fairness and may initiate future legal actions.
Biofrontera AG (NASDAQ: BFRA), a biopharmaceutical company based in Germany, will announce its first quarter 2020 unaudited financial results on May 19, 2020. Shareholders and investors are invited to join conference calls on May 20, 2020, with sessions in both German and English. The company specializes in dermatological drugs and medical cosmetics, with notable products like Ameluz® and Xepi™. Biofrontera is recognized for being the first German founder-led pharmaceutical firm to gain both European and US drug approvals.